Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a
decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may …

Background Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations.
Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts …

Background Some patients with severe asthma have frequent exacerbations associated with
persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …

The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …

Asthma is responsible for considerable global morbidity and health-care costs. Substantial
progress was made against key outcomes such as hospital admissions with asthma and …

BETWEEN BEDSIDE AND BENCH differentiation of naive T lymphocytes toward TH2 cells,
which produce cytokines such as interleukin-4 (IL-4), IL-5, IL-9 and IL-13 (ref. 2). Allergic TH2-…

GINA no longer recommends treating adults/adolescents with asthma with short-acting
bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily …

Chronic obstructive pulmonary disease (COPD) is a heterogeneous syndrome associated
with abnormal inflammatory immune responses of the lung to noxious particles and gases. …

Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent chronic airway
diseases that have a high personal and social impact. They likely represent a continuum of …